Dr Miron on the Characteristics of Intraductal Carcinoma of the Prostate

Benjamin Miron, MD, medical oncologist, researcher, Fox Chase Cancer Center, discusses the rationale for investigating molecular alterations in patients with intraductal carcinoma of the prostate.

At the 2023 ASCO Annual Meeting, Miron and colleagues shared data on the results of a study that investigated these molecular alterations. Investigators analyzed tissue samples from patients who underwent radical prostatectomy and conducted DNA and RNA sequencing to gather comprehensive molecular profiling data from the largest cohort of patients with intraductal carcinoma of the prostate reported to date in order to better characterize this histology.

Findings showed that a proportion of patients with intraductal carcinoma of the prostate harbored targetable molecular alterations in mutations such as BRCA1 mutations (3.2%), BRCA2 mutations (3.3%), and CDK12alterations (9.7%). Of the 31 evaluable patients, the most frequently detected alterations were TMPRSS2 fusions (38.7%), TP53 alterations (38.7%), FOXA1 alterations (16.1%), SPOP alterations (9.7%), CDK12alterations (9.7%), and PIK3CA alterations (9.7%).

Intraductal carcinoma of the prostate was first included in the World Health Organization (WHO) tumor classification in 2016, Miron notes. Moreover, important clinical characteristics of intraductal carcinoma of the prostate include higher volume and more aggressive tumors that are most likely to spread, Miron explains.

Since intraductal carcinoma of the prostate is still a relatively new addition to the WHO classification, this study aimed to provide more data about the molecular profile of this histology and some of the drivers that may differentiate it from other histologies, Miron concludes.